DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,051,392 | +27.9% | 56,636 | +23.7% | 1.91% | +5.8% |
| Q2 2023 | $10,985,520 | -5.2% | 45,773 | -0.4% | 1.80% | -10.6% |
| Q1 2023 | $11,584,010 | -7.8% | 45,961 | -2.9% | 2.02% | -8.5% |
| Q4 2022 | $12,557,285 | +3.1% | 47,311 | +0.3% | 2.20% | -2.9% |
| Q3 2022 | $12,181,000 | +1.0% | 47,161 | -0.9% | 2.27% | +9.0% |
| Q2 2022 | $12,066,000 | -15.5% | 47,596 | -2.2% | 2.08% | +0.2% |
| Q1 2022 | $14,275,000 | -10.4% | 48,667 | +0.5% | 2.08% | -3.2% |
| Q4 2021 | $15,929,000 | +8.5% | 48,417 | +0.4% | 2.15% | -1.4% |
| Q3 2021 | $14,677,000 | +18.0% | 48,208 | +4.1% | 2.18% | +18.3% |
| Q2 2021 | $12,433,000 | +22.5% | 46,328 | +2.8% | 1.84% | +14.5% |
| Q1 2021 | $10,146,000 | +3.0% | 45,079 | +1.7% | 1.61% | -2.5% |
| Q4 2020 | $9,848,000 | -1.5% | 44,334 | -4.5% | 1.65% | -12.5% |
| Q3 2020 | $10,001,000 | +21.2% | 46,444 | -0.4% | 1.89% | +11.4% |
| Q2 2020 | $8,249,000 | +26.8% | 46,649 | -0.8% | 1.69% | +10.6% |
| Q1 2020 | $6,507,000 | -8.4% | 47,014 | +1.5% | 1.53% | +14.9% |
| Q4 2019 | $7,106,000 | +5.9% | 46,304 | -0.4% | 1.33% | -0.1% |
| Q3 2019 | $6,713,000 | +1.7% | 46,480 | +0.7% | 1.34% | -1.0% |
| Q2 2019 | $6,599,000 | +13.4% | 46,170 | +4.8% | 1.35% | +9.5% |
| Q1 2019 | $5,818,000 | +31.5% | 44,065 | +2.7% | 1.23% | +15.9% |
| Q4 2018 | $4,425,000 | +1.6% | 42,907 | +7.1% | 1.06% | +13.0% |
| Q3 2018 | $4,354,000 | +12.9% | 40,067 | +2.5% | 0.94% | +4.9% |
| Q2 2018 | $3,856,000 | +12.6% | 39,077 | +11.8% | 0.90% | +9.3% |
| Q1 2018 | $3,423,000 | +51.7% | 34,967 | +43.8% | 0.82% | +31.6% |
| Q4 2017 | $2,257,000 | +15.3% | 24,312 | +6.5% | 0.62% | +6.5% |
| Q3 2017 | $1,958,000 | +2.2% | 22,822 | +0.5% | 0.59% | -4.9% |
| Q2 2017 | $1,916,000 | +0.3% | 22,712 | +1.7% | 0.62% | -3.8% |
| Q1 2017 | $1,910,000 | +12.0% | 22,325 | +1.9% | 0.64% | +8.7% |
| Q4 2016 | $1,705,000 | +0.9% | 21,905 | +1.7% | 0.59% | -0.8% |
| Q3 2016 | $1,689,000 | -14.3% | 21,545 | +10.4% | 0.59% | -15.5% |
| Q2 2016 | $1,971,000 | +9.0% | 19,515 | +2.4% | 0.70% | +3.8% |
| Q1 2016 | $1,808,000 | +0.1% | 19,055 | -2.1% | 0.68% | +19.6% |
| Q4 2015 | $1,807,000 | +22.5% | 19,455 | +12.4% | 0.57% | +14.6% |
| Q3 2015 | $1,475,000 | +0.2% | 17,315 | +0.7% | 0.49% | +8.1% |
| Q2 2015 | $1,472,000 | -2.0% | 17,195 | -2.8% | 0.46% | -4.0% |
| Q1 2015 | $1,502,000 | -0.6% | 17,695 | +0.4% | 0.48% | +0.2% |
| Q4 2014 | $1,511,000 | +11.8% | 17,626 | -0.8% | 0.48% | +5.8% |
| Q3 2014 | $1,351,000 | 0.0% | 17,776 | +3.6% | 0.45% | -1.1% |
| Q2 2014 | $1,351,000 | +6.0% | 17,156 | +1.0% | 0.45% | +0.7% |
| Q1 2014 | $1,274,000 | +4.9% | 16,988 | +7.9% | 0.45% | +4.6% |
| Q4 2013 | $1,215,000 | +11.3% | 15,746 | 0.0% | 0.43% | +0.7% |
| Q3 2013 | $1,092,000 | +8.3% | 15,746 | -1.1% | 0.43% | +1.9% |
| Q2 2013 | $1,008,000 | – | 15,926 | – | 0.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |